The C-terminal tripeptide of alpha-MSH (lysine-proline-valine), studied mostly in cell and animal models for anti-inflammatory and gut-healing effects.
Reviewed for accuracy · Last reviewed July 7, 2026KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied for anti-inflammatory activity, and the notable mechanistic finding is that this activity appears to persist even without melanocortin receptors, so KPV likely acts through a receptor-independent route rather than the classic melanocortin pathway.
Most of what is known comes from cell and animal models, with a particular focus on intestinal inflammation: in mouse colitis models, orally administered KPV is taken up by the PepT1 transporter in the gut and dampens NF-kB and related inflammatory signaling. Human clinical evidence is essentially absent, so specific claims about what KPV does in people should be treated as preliminary.
There is no established human dose. Community protocols cite roughly 200 – 500 mcg once daily by injection, extrapolated from preclinical work rather than human trials. KPV is not FDA-approved.
Read the full KPV dosage guide →Human safety data is essentially absent because no adequately powered human trials exist. Reported effects are mostly local, such as injection-site irritation, and the honest caveat is that its human safety profile is not characterized.
Read the full KPV side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.